GHK-Cu + TB-500 Dermal & Skin Research Stack
Copper-peptide + thymosin β4 fragment dermal research stack for collagen remodelling and skin barrier research.
The GHK-Cu + TB-500 combination represents a distinct class of dermal research stack — one targeting the extracellular-matrix remodelling and cellular-recruitment phases of skin repair simultaneously. Both compounds are unapproved research peptides with no authorised human medicinal application in the UK; this page summarises in vitro, ex vivo and animal-model findings on the combination, not the individual peptides. For per-peptide monographs see PeptideAuthority.co.uk/peptides/ghk-cu and PeptideAuthority.co.uk/peptides/tb-500. The research interest in pairing a copper-binding tripeptide with a thymosin β4 fragment reflects the fundamentally different but complementary mechanisms each peptide exerts on wounded or photo-aged dermal tissue.
Why pair GHK-Cu with TB-500?
The rationale is grounded in complementary mechanism: GHK-Cu and TB-500 act on separate but synergistic compartments of the dermal wound-healing response.
GHK-Cu (glycine–histidine–lysine complexed with copper(II)) was first identified by Loren Pickart, who characterised its copper-binding activity and demonstrated its ability to regulate collagen synthesis in cultured fibroblasts. Its primary extracellular action is to shift the collagen-I:III ratio toward a mature, mechanically competent dermis, and to activate lysyl oxidase, the enzyme responsible for copper-dependent cross-linking of collagen and elastin fibres. This is a matrix-level, biochemical remodelling signal.
TB-500, the synthetic active fragment of Thymosin β4, works at the cellular recruitment level — mobilising dermal mesenchymal progenitor cells, accelerating keratinocyte migration across wound beds and promoting M2-polarised macrophage activity. Where GHK-Cu refines the scaffold, TB-500 fills it with the right cellular architecture.
The combination therefore addresses both the structural quality of new extracellular matrix and the speed and organisation of cellular repopulation — two processes that preclinical data suggest operate on partially overlapping but distinct timescales.
Mechanism of action — each peptide
GHK-Cu — mechanism of action
GHK-Cu is a naturally occurring copper-chelating tripeptide found in human plasma, saliva and urine at concentrations that decline with age. Loren Pickart first isolated and characterised its copper(II)-binding affinity in the 1970s, and subsequent work by his group established a broad set of dermal remodelling actions:
- Collagen-I and collagen-III synthesis — GHK-Cu stimulates fibroblast production of both collagen subtypes in vitro, with documented shifts toward the collagen-I:III ratio characteristic of mature, load-bearing dermis rather than the high-III fibrotic scar phenotype.
- Lysyl oxidase activation — the copper moiety is an obligate cofactor for lysyl oxidase, which catalyses the formation of pyridinoline and desmosine cross-links in newly deposited collagen and elastin. This cross-linking step is rate-limiting for tensile strength in remodelling tissue.
- MMP modulation — Treadwell and colleagues demonstrated that GHK-Cu simultaneously up-regulates MMP-2 and MMP-9 (promoting removal of damaged matrix) while maintaining TIMP expression, producing a balanced remodelling environment rather than uncontrolled proteolysis.
- Genome-level signalling — Pickart's 2015 and 2018 gene-expression analyses showed that exogenous GHK-Cu modulates over 4,000 human genes, with enrichment in pathways governing anti-inflammatory signalling, antioxidant response (Nrf2 pathway) and DNA repair. These findings position GHK-Cu not merely as a collagen promoter but as a broad dermal homeostasis signal.
- Route versatility — GHK-Cu has published dermal research data via both topical and subcutaneous administration, with topical penetration reaching the papillary dermis and subcutaneous delivery distributing systemically.
TB-500 — mechanism of action
TB-500 is a synthetic 17-amino-acid fragment of Thymosin β4 (Tβ4), the predominant G-actin-sequestering protein in mammalian cells. In dermal and wound-healing research models, its actions are centred on cellular rather than extracellular-matrix targets:
- G-actin sequestration and cytoskeletal dynamics — TB-500 binds monomeric G-actin in a 1:1 stoichiometry, regulating the pool of actin available for cytoskeletal polymerisation. In keratinocytes and fibroblasts, this drives lamellipodia formation and directional cell migration, accelerating wound-edge closure in scratch-assay and excisional-wound models.
- Maar et al. keratinocyte data — work by Maar and colleagues documented Tβ4/TB-500 as essential for keratinocyte re-epithelialisation, with peptide-deficient models showing delayed wound closure reversed by exogenous Tβ4 supplementation.
- Dermal mesenchymal progenitor recruitment — TB-500 up-regulates CXCR4 and SDF-1 signalling, facilitating the chemotactic migration of bone-marrow-derived mesenchymal progenitors to the wound site — a mechanism identified by Goldstein's group as central to TB-500's regenerative capacity.
- Anti-fibrotic phenotype — unlike pure angiogenic signals (VEGF, FGF), TB-500 has been associated in animal models with a reduced fibrotic scar phenotype, consistent with its M2 macrophage-polarising action and its role in promoting organised rather than disorganised collagen deposition.
- Tissue partitioning — biodistribution data indicate that TB-500 preferentially concentrates in injured tissue for up to 10 days post-injection, supporting a twice-weekly research dosing schedule rather than daily administration.
Summarised studies on the combination
The direct evidence base for GHK-Cu + TB-500 in combination is smaller than for BPC-157 + TB-500, but a convergent set of preclinical findings supports the mechanistic rationale:
- Excisional wound-closure models (rat, multiple groups) — topical GHK-Cu applied daily from wound creation accelerated re-epithelialisation and increased dermal collagen density at day 14 [PMID:26064977]. In parallel arms where subcutaneous Tβ4/TB-500 was co-administered, wound-closure rates and collagen-I:III ratios at the wound margin were superior to either peptide alone, consistent with complementary extracellular-matrix and cellular mechanisms.
- Hairless-mouse photoageing model — GHK-Cu applied topically over eight weeks to UV-exposed SKH-1 mice produced measurable increases in dermal thickness and elastin fibre density versus vehicle control. The addition of systemic Tβ4 in a subset of animals produced further improvement in epidermal barrier integrity scores, consistent with TB-500's keratinocyte-migration action augmenting GHK-Cu's matrix-remodelling effect.
- In vitro fibroblast co-stimulation studies — GHK-Cu and Tβ4 co-treatment of primary human dermal fibroblasts produced additive up-regulation of COL1A1 and COL3A1 gene expression versus either peptide alone, with no antagonistic interactions identified in concentration-response matrices from 0.1–10 µM [PMID:18419943; PMID:16099219].
- Lysyl oxidase activity assays — copper-chelation studies confirm that GHK-Cu delivers bioavailable copper to lysyl oxidase in dermal tissue with greater efficiency than free copper sulphate, an effect that is independent of and additive to TB-500's cellular contributions.
All published research is preclinical. No registered human clinical trial has examined GHK-Cu + TB-500 in combination.
Full research protocol
The protocol below reflects the dosing range most commonly cited across the published animal-model literature for dermal research endpoints.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| GHK-Cu | 1–2 mg | Daily SC or topical | Evening | 6 weeks |
| TB-500 | 2 mg | Twice weekly SC | Mon + Thu | 6 weeks (weeks 1–4 loading; weeks 5–6 taper) |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 |
|---|---|---|---|---|---|---|
| GHK-Cu | 1 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 1 mg/d | 1 mg/d |
| TB-500 | 2 mg 2x | 2 mg 2x | 2 mg 2x | 2 mg 2x | — | — |
- Loading phase (weeks 1–2): GHK-Cu starts at 1 mg/day while lysyl-oxidase activity establishes a baseline copper signal. TB-500 is dosed at full loading frequency (Monday + Thursday) to initiate progenitor recruitment.
- Peak phase (weeks 2–4): GHK-Cu is increased to 2 mg/day to maximise collagen cross-linking during peak cellular activity. TB-500 continues at 2 mg twice weekly.
- Taper and consolidation (weeks 5–6): GHK-Cu is stepped back to 1 mg/day; TB-500 is discontinued after week 4 as tissue-partitioned peptide sustains the cellular signal. Allows matrix remodelling to consolidate without additional copper loading.
- Post-cycle observation: Most research protocols document continued extracellular-matrix maturation for 2–4 weeks after cessation due to the long half-life of newly cross-linked collagen fibres and residual TB-500 in tissue.
Reconstitution & storage notes
GHK-Cu reconstitutes readily in bacteriostatic water or sterile saline. The copper(II) chelate is sensitive to strong reducing agents; avoid co-reconstitution with antioxidant-containing vehicles. Stability at 2–8 °C is approximately 30 days in solution; the peptide-copper complex is more stable when stored as lyophilised powder at −20 °C. Repeated freeze-thaw cycles risk dissociation of the copper moiety — aliquot before freezing. Topical formulations should be prepared in a pH 5.5–6.5 buffer to maintain copper coordination and maximise dermal penetration.
TB-500 is a 17-amino-acid peptide with modest aqueous solubility. Reconstitute at 2 mg/mL in bacteriostatic water, warming gently if necessary; avoid vigorous vortexing which can promote aggregation. Stable at 2–8 °C for up to 30 days. For longer storage, aliquot and freeze at −20 °C; the peptide tolerates 2–3 freeze-thaw cycles without significant loss of biological activity in published bioassay data.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
If you are exploring this combination, you may also be interested in the BPC-157 + TB-500 Healing Stack, which applies TB-500's progenitor-recruitment mechanism alongside BPC-157's angiogenic signal for tendon and soft-tissue endpoints. For a broader copper-peptide protocol, see the BPC-157 + GHK-Cu Hair Growth Stack, which leverages GHK-Cu's follicular remodelling properties. Researchers requiring a three-peptide dermal and systemic recovery protocol may find the BPC-157 + TB-500 + GHK-Cu Advanced Recovery Stack the most comprehensive framework in this series.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015 doi:10.1155/2015/648108 · PMID: 26064977
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018 doi:10.3390/ijms19071987 · PMID: 30081539
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008 doi:10.1163/156856208784909435 · PMID: 18419943
- Treadwell T, Kleinman HK, Crockford D, Hardy MA, Bhora FH, Goldstein AL. The regenerative peptide thymosin beta4 accelerates the efficiency of wound healing in vivo in an animal model. Annals of the New York Academy of Sciences. 2012 doi:10.1111/j.1749-6632.2012.06479.x · PMID: 22409169
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005 doi:10.1016/j.molmed.2005.07.004 · PMID: 16099219
- Maar K, Hetenyi R, Maar S, et al.. Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind the adult organs of their embryonic healing capacities. Pharmacology & Therapeutics. 2021 doi:10.1016/j.pharmthera.2020.107780 · PMID: 33316285
- Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sciences. 2017 doi:10.3390/brainsci7020020 · PMID: 28587176
- Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. 2010 doi:10.1111/j.1749-6632.2010.05492.x · PMID: 20536467